Year :
2015
| Month :
June
| Volume :
9
| Issue :
6
| Page :
FC07 - FC10
Full Version
Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride
Published: June 1, 2015 | DOI: https://doi.org/10.7860/JCDR/2015/.6066
TS Deepak, BN Raveesh, BM Parashivamurthy, MS Narendra Kumar, Sumanth Mallikarjuna Majgi, HN Nagesh
1. Postgraduate, Department of Pharmacology, MMC&RI, Mysore, India.
2. Professor and Head, Department of Psychiatry, MMC&RI, Mysore, India.
3. Professor and Head, Department of Pharmacology, MMC&RI, Mysore, India.
4. Assistant Professor, Department of Psychiatry, MMC&RI, Mysore, India.
5. Assistant Professor, Department of Community Medicine, MMC&RI, Mysore, India.
6. Assistant Professor, Department of Pharmacology, MMC&RI, Mysore, India.
Correspondence Address :
Dr. Deepak.T.S,
Postgraduate, Department of Pharmacology, Mysore Medical College and Research Institute,
Irvin Road, Mysore-570001, India.
E-mail : deepak.ts123@gmail.com
Abstract
Background: Atypical antipsychotics appear to have the greatest potential to induce weight gain. Antipsychotic-induced weight gain is the one of main cause of non-compliance and discontinuation of treatment, often resulting in the relapse of psychosis. Objective: To compare the weight gain between amisulpride and blonanserin treatment, in persons with psychosis. Materials and Methods: Fifty six subjects with psychosis attending psychiatry department at KR Hospital, Mysore were randomized into two equal groups. After obtaining informed consent, subjects of group I received amisulpride tablets 200 mg BD, and group II received blonanserin tablets 4 mg BD, for eight weeks. Body weight, Body Mass Index (BMI) and Waist Hip Ratio (WHR) were measured at baseline, 4 weeks and 8 weeks. R esults: The mean weight gain with amisulpride at 4 weeks was 2.73 kg (5.21%) and at 8 weeks was 4.34 kg (8.28%) from the baseline. The mean weight gain with blonanserin at 4 weeks was 1.77 kg (3.46%) and at 8 weeks was 3.46 kg (6.75%) from the baseline. The mean BMI increase at 8 weeks with amisulpride was 1.66 ± 0.56 and with blonanserin was 1.34 ± 0.77. The mean WHR increase at 8 weeks with amisulpride was 0.036 ± 0.026 and with blonanserin was 0.029 ± 0.020. There was statistically significant increase in weight, BMI and WHR associated with both blonanserin and amisulpride at 8 weeks. But there was no statistically significant difference in those parameters between blonanserin and amisulpride, at eight weeks. C onclusion: Even though there was no significant difference in the weight gain caused by blonanserin, in comparison with amisulpride, both these drugs individually caused significant weight gain at 8 weeks, which is in contrast with the earlier studies, which needs to be further evaluated.
Keywords
Metabolic adverse effects, Psychosis, Randomized controlled trial
DOI: 10.7860/JCDR/2015/13007.6066
Date of Submission: Jan 14, 2015
Date of Peer Review: Apr 18, 2015
Date of Acceptance: Apr 22, 2015
Date of Publishing: Jun 01, 2015
Financial OR OTHER COMPETING INTERESTS: None.
|